Immuneering IMRX 深 滬
已收盤 11-06 16:00:00 美东时间
3.68
+0.310
+9.20%
華盛通- 最 高3.70
- 今 開3.41
- 成交量 68.15万股
- 最 低 3.3683
- 昨 收 3.37
- 總市值 2.38亿
- 52周最高 8.48
- 市盈率 靜 --
- 換手率 1.05%
- 52周最低 3.35
- 委 比 9.09%
- 總股本 6476.32万
- 歷史最高 33.99
- 量 比 0.79
- 振 幅 9.84%
- 歷史最低 1.00
- 每 手 1
- 風險率 0.91%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Immuneering收涨2.17%，成交额275.38万美元
11月5日，Immuneering（IMRX）收涨2.17%，报3.76美元，成交额275.38万美元，市值2.44亿美元。 行情数据 • 开盘价：3.74美元...
11-05 07:36
Immuneering to Highlight Atebimetinib’s Broad Potential for Combinations in Pancreatic and Anaplastic Thyroid Cancers at the 2026 EORTC-NCI-AACR Symposium
<p>Immuneering Corporation announced that two abstracts on atebimetinib, its lead investigational candidate targeting the MAPK pathway, have been accepted for presentation at the 2026 EORTC-NCI-AACR Symposium. The presentations will highlight new preclinical findings supporting atebimetinib's potential in combination therapies for pancreatic ductal adenocarcinoma (PDAC) and anaplastic thyroid cancer (ATC). Atebimetinib has shown promising results...
11-04 12:30
Immuneering收跌6.81%，成交额284.71万美元
11月3日，Immuneering（IMRX）收跌6.81%，报3.49美元，成交额284.71万美元，市值2.26亿美元。 行情数据 • 开盘价：3.76美元...
11-03 07:34
Immuneering收跌0.54%，成交额215.15万美元
10月27日，Immuneering（IMRX）收跌0.54%，报3.71美元，成交额215.15万美元，市值2.4亿美元。 行情数据 • 开盘价：3.73美元...
10-27 06:35
Immuneering Presents Design and Methodology of Ongoing Phase 3 MAPKeeper 301 Trial at ESMO Congress 2026
Immuneering Corporation announced the initiation of the MAPKeeper 301 pivotal Phase 3 trial evaluating atebimetinib combined with modified gemcitabine/nab-paclitaxel (mGnP) in first-line metastatic pancreatic ductal adenocarcinoma (PDAC). The trial aims to assess whether this combination improves overall survival compared to standard-of-care chemotherapy. MAPKeeper 301 builds on encouraging Phase 2a results showing a median overall survival of 17...
10-26 11:30
Immuneering收涨1.91%，成交额347.51万美元
10月21日，Immuneering（IMRX）收涨1.91%，报3.73美元，成交额347.51万美元，市值2.41亿美元。 行情数据 • 开盘价：3.7美元...
10-21 06:37
Immuneering收跌1.37%，成交额270.52万美元
10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-17 06:39
Immuneering to Present at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
<p>Immuneering Corporation announced that atebimetinib enhances PD-1 checkpoint blockade in preclinical RAS mutant tumor models, supporting an upcoming Phase 2 study in lung cancer patients. The findings will be presented at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in Phoenix, AZ, on November 6, 2026. The poster, titled "Cyclic disruption of the mitogen-activated protein kinase (MAPK) pathway by the pulsatile MEK ...
10-02 13:00
Immuneering to Present at the ESMO Congress 2026
<p>Immuneering Corporation announced that an abstract on its Phase 3 MAPKeeper 301 trial of atebimetinib combined with modified gemcitabine/nab-paclitaxel (mGnP) for first-line pancreatic cancer treatment has been accepted for a poster presentation at the ESMO Congress 2026 in Madrid. The trial aims to evaluate the efficacy and safety of this combination in patients with metastatic pancreatic ductal adenocarcinoma. Full abstracts will be availabl...
09-24 11:30
Immuneering To Present Data At American Association For Cancer Research Conference On Pancreatic Cancer: New Frontiers In Biology And Therapeutic Development
Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced it will present a poster at the American Association for Cancer Research (AACR) Conference on Pancreatic Cancer: New Frontiers in Biology a...
09-10 19:32
